Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market
完整報告名稱與涵蓋範圍
Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Size, Share & Trends Analysis Report, By Intervention Type (Oral Pharmacological and Metabolic Aids, Endoscopic Bariatric Devices and Procedures, Non-Invasive Metabolic and Digital Interventions), By Indication (Obesity with BMI 30-40, Obesity with Metabolic Comorbidities, Weight Regain After Bariatric Surgery), By End User (Hospitals and Bariatric Centers, Ambulatory Endoscopy Centers, Obesity Medicine and Telehealth Clinics), By Distribution Channel, By Region, and Segment Forecasts, 2026-2035
報告摘要
The alternatives to bariatric surgery market covers oral pharmacological and metabolic aids, endoscopic bariatric devices and procedures, and non-invasive metabolic interventions used to treat obesity and related metabolic disease without surgical anatomy change, including intragastric balloons, endoscopic sleeve gastroplasty tooling, duodenal interventions, oral obesity medicines and structured digital-medical programs. Surgical procedures and injectable incretin therapies are excluded from revenue but modelled as the competitive frame that shapes demand.
The category has been transformed by the reach of incretin drugs, which reduced bariatric surgery volumes while creating new demand for oral agents, maintenance strategies and interventions for patients who cannot access, afford or tolerate injectables. Endoscopic procedures offer durable weight loss at lower cost and risk than surgery, and reimbursement is widening in the United States and parts of Europe, while duodenal mucosal resurfacing and swallowable balloons extend the non-surgical toolkit. Oral small-molecule incretins approaching the market will further blur the boundary between drugs and procedures and intensify competition for the moderate-obesity population.
North America leads adoption, followed by Europe, the Middle East and Latin America where endoscopic therapies are well established; Asia Pacific growth is driven by rising obesity prevalence and lower surgical acceptance. Competition spans obesity pharmaceutical franchises, endoscopic device makers and metabolic procedure innovators.
The InsightAce study supplies US$ forecasts for all intervention type, indication, end user and distribution channel and regional segments over 2026-2035, segment-level trend analysis, competitive landscape assessment and profiling of the leading companies.
授權報價
| Single User | $4,500 USD |
| Enterprise / Global Site Licence | $9,500 USD |
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Snapshot
Chapter 4. Global Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Market Drivers
4.3. Market Challenges
4.4. Emerging Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis - Porter's Five Forces Analysis
4.7. Competitive Landscape and Market Positioning
4.8. Market Opportunity Analysis
Chapter 5. Market Segmentation 1: By Intervention Type Estimates & Trend Analysis
5.1. Intervention Type & Market Share, 2026 & 2035
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Intervention Type:
5.2.1. Oral Pharmacological and Metabolic Aids
5.2.2. Endoscopic Bariatric Devices and Procedures
5.2.3. Non-Invasive Metabolic and Digital Interventions
Chapter 6. Market Segmentation 2: By Indication Estimates & Trend Analysis
6.1. Indication & Market Share, 2026 & 2035
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Indication:
6.2.1. Obesity with BMI 30-40
6.2.2. Obesity with Metabolic Comorbidities
6.2.3. Weight Regain After Bariatric Surgery
Chapter 7. Market Segmentation 3: By End User Estimates & Trend Analysis
7.1. End User & Market Share, 2026 & 2035
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by End User:
7.2.1. Hospitals and Bariatric Centers
7.2.2. Ambulatory Endoscopy Centers
7.2.3. Obesity Medicine and Telehealth Clinics
Chapter 8. Market Segmentation 4: By Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel & Market Share, 2026 & 2035
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analysis, 2026 to 2035, by Distribution Channel:
8.2.1. Direct Institutional Sales
8.2.2. Retail and Online Pharmacies
Chapter 9. Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. United States
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. United Kingdom
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. South Korea
9.3.5. Australia
9.3.6. Southeast Asia
9.3.7. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. GCC Countries
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Landscape
10.1. Company Market Positioning Analysis
10.2. Strategic Developments (Partnerships, Expansions, Product Launches, M&A)
Chapter 11. Company Profiles
11.1. Novo Nordisk A/S
11.2. Eli Lilly and Company
11.3. Boston Scientific Corporation (Apollo Endosurgery)
11.4. Allurion Technologies, Inc.
11.5. ReShape Lifesciences Inc.
11.6. Spatz Medical
11.7. Fractyl Health, Inc.
11.8. Glyscend Therapeutics
11.9. AltrixBio, Inc.
11.10. Endogenex, Inc.
11.11. GI Dynamics, Inc.
11.12. Nitinotes Ltd.
11.13. Medtronic plc
11.14. Olympus Corporation
11.15. Pfizer Inc.
圖表清單 List of Tables & Figures
Table 1. Global Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Revenue Forecast by Intervention Type, 2026-2035 (US$ Mn)
Figure 1. Global Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Segmentation and Scope Overview
Table 2. Global Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Revenue Forecast by Indication, 2026-2035 (US$ Mn)
Figure 2. Global Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Share by Intervention Type, 2026 & 2035
Table 3. Global Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Revenue Forecast by End User, 2026-2035 (US$ Mn)
Figure 3. Obesity Intervention Continuum from Lifestyle to Surgery: Positioning of Non-Surgical Options
Table 4. Global Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Revenue Forecast by Distribution Channel, 2026-2035 (US$ Mn)
Figure 4. Effect of Incretin Therapies on Bariatric Surgery and Endoscopic Procedure Volumes, 2022-2035
Table 5. Global Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Revenue Forecast by Region, 2026-2035 (US$ Mn)
Figure 5. Asia Pacific Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Growth Opportunity Analysis
Table 6. North America Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 6. Competitive Positioning of Key Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Participants
Table 7. Europe Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 7. Porter's Five Forces Analysis of the Global Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market
Table 8. Asia Pacific Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Revenue by Country, 2026-2035 (US$ Mn)
Figure 8. Reimbursement Status of Endoscopic Bariatric Procedures by Country
Table 9. Strategic Developments of Leading Alternatives to Bariatric Surgery (Oral, Endoscopic & Non-Invasive Metabolic Interventions) Market Participants, 2023-2026
提及公司
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們